
Cat. #161909
Tera-2 Cell Line
Cat. #: 161909
Availability: 8-10 weeks
Organism: Human
Tissue: Lung
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Jorgen Fogh
Institute: Memorial Sloan-Kettering Cancer Center (MSK)
Primary Citation: Fogh et al. 1977. Journal of the National Cancer Institute. 59: 221-226. PMID: 327080.
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Tera-2 Cell Line
- Cancer type: Lung cancer
- Organism: Human
- Gender: Male
- Tissue: Lung
- Morphology: Epithelial
- Growth properties: Adherent
- Description: Human Carcinoma Cell Line Derived from a Lung Metastatic Site.
- Application: 3D cell culture; Cancer research
- Biosafety level: 1
Target Details
- Target: Antigen expression: Blood Type A; Rh+
Applications
- Application: 3D cell culture; Cancer research
Handling
- Growth medium: McCoy's 5a Medium Modified supplemented with 15% FBS
- Temperature: 37° C
- Atmosphere: 95% Air, 5% CO2
- Shipping conditions: Dry Ice
- Storage medium: Culture medium 95%; DMSO, 5%
- Storage conditions: Vapor phase of liquid nitrogen. Storage at -70° C will result in loss of viability.
- Subculture routine: Subcultures are prepared by scraping. Remove spent medium, add fresh, dislodge cells from the floor of the flask, aspirate to disperse and dispense into new flasks. Subculture about once a week. Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended Medium Renewal: 2 to 3 times per week
- Str profiling: Amelogenin: X,Y;CSF1PO: 10,12;D13S317: 13;D16S539: 11,12,13;D5S818: 9,12;D7S820: 10,12;TH01: 9.3;TPOX: 8;vWA: 18,19;D3S1358: 16;D21S11: 30,31;D18S51: 14;Penta_E: 5,14;Penta_D: 12,13;D8S1179: 13,15;FGA: 23;D19S433: 14,15.2;D2S1338: 22,25
References
- Fogh J et al. 1977. Journal of the National Cancer Institute. 59: 221-226. PMID: 327080.
![Anti-CAR Whitlow Linker [1C3C3]](https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-300x322.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-280x300.jpg 280w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-954x1024.jpg 954w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-768x824.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 1193w)

![Anti-CAR Whitlow Linker [1B4A1]](https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-300x396.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-227x300.jpg 227w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-776x1024.jpg 776w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-768x1013.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 970w)
